The role of adipose tissue dysfunction in schizophrenia, and in particular the role of circulating adiponectin levels, could provide a useful biomarker to classify cardiovascular risk in patients with schizophrenia, as it has already shown to have potential as a predictor of developing metabolic syndrome in this same cohort [51, 52]. The gene discussed is ADIPOQ; the disease is metabolic syndrome.